Trials / Active Not Recruiting
Active Not RecruitingNCT04624178
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rucaparib | Rucaparib at 600 mg, orally, twice daily, continuously for 28 days. |
| DRUG | Nivolumab | Nivolumab 480mg intravenously on day 1 of every four-week cycle. |
Timeline
- Start date
- 2020-11-05
- Primary completion
- 2026-11-16
- Completion
- 2026-11-16
- First posted
- 2020-11-10
- Last updated
- 2025-11-20
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04624178. Inclusion in this directory is not an endorsement.